Tscan Therapeutics Inc Market Cap ($12.83 Million)
Market Cap & Net Worth: Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc market cap. Tscan Therapeutics Inc (NASDAQ:TCRX) has a market capitalization of $12.83 Million ($12.83 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26267 globally and #5510 in its home market, demonstrating a 9.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tscan Therapeutics Inc's stock price $0.21 by its total outstanding shares 61074229 (61.07 Million). Also see TCRX operating cash flow for how efficiently the company converts equity into cash flow.
Tscan Therapeutics Inc Market Cap History (2021–2026)
Tscan Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $274.83 Million to $12.83 Million (-52.15% CAGR). Check TCRX stock price for real-time trading data and today's change.
Index Memberships
Tscan Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #735 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2405 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.00% | #251 of 263 |
Weight: Tscan Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tscan Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tscan Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Tscan Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.92x
Tscan Therapeutics Inc's market cap is 5.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $274.83 Million | $10.14 Million | -$48.62 Million | 27.10x | N/A |
| 2022 | $94.67 Million | $13.54 Million | -$66.22 Million | 6.99x | N/A |
| 2023 | $356.06 Million | $21.05 Million | -$89.22 Million | 16.92x | N/A |
| 2024 | $185.67 Million | $2.82 Million | -$127.50 Million | 65.93x | N/A |
| 2025 | $61.07 Million | $10.32 Million | -$129.77 Million | 5.92x | N/A |
Competitor Companies of TCRX by Market Capitalization
Companies near Tscan Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Tscan Therapeutics Inc for a full breakdown of the balance sheet.
Key companies related to Tscan Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Tscan Therapeutics Inc (2021–2026)
Market capitalization of Tscan Therapeutics Inc from 2021 to today. Between 2021 and today, Tscan Therapeutics Inc's market cap moved from $274.83 Million to $ 12.83 Million, with a yearly change of -52.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.83 Million | -79.00% |
| 2025 | $61.07 Million | -67.11% |
| 2024 | $185.67 Million | -47.86% |
| 2023 | $356.06 Million | +276.13% |
| 2022 | $94.67 Million | -65.56% |
| 2021 | $274.83 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Tscan Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.83 Million USD |
| MoneyControl | $12.83 Million USD |
| MarketWatch | $12.83 Million USD |
| marketcap.company | $12.83 Million USD |
| Reuters | $12.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more